Sign In
Buy ABUS
$4.26
-0.220 (-4.91%)
At Close: Jun 02, 2026
Arbutus Biopharma Corporation (ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced positive preliminary results from a Phase 1a/1b clinical trial (AB-729-001) in healthy su
AstraZeneca Joins RNAi Mix, Pledging $80M to Silence Therapeutics
07:00pm, Wednesday, 25'th Mar 2020
After years of research, technology for silencing a gene---stopping it from producing a disease-causing protein---has reached patients. AstraZeneca is now
Arbutus Biopharma (ABUS) Receives a Buy from B.Riley FBR
12:30pm, Monday, 16'th Mar 2020
B.Riley FBR analyst Mayank Mamtani maintained a Buy rating on Arbutus Biopharma (ABUS) on March 13 and set a price target of $6.00. The company's shares
Arbutus Biopharma (ABUS) Receives a Buy from B.Riley FBR
12:30pm, Monday, 16'th Mar 2020
B.Riley FBR analyst Mayank Mamtani maintained a Buy rating on Arbutus Biopharma (ABUS – Research Report) on March 13 and
Goldman likes GW Pharma in premarket analyst action
12:22pm, Friday, 06'th Mar 2020
ACADIA Pharmaceuticals (NASDAQ:ACAD) initiated with Buy rating and $69 (55% upside) price target at Citigroup.Alector (NASDAQ:ALEC) initiated with Buy rating and $40 (36% upside) price target at Citi.
The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19
01:05pm, Thursday, 05'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 4) * 89bio Inc (NASDAQ: ETNB) * Arcus Biosciences In
Arbutus Reports Fourth Quarter and Year End 2019 Financial Results, Confirms 2020 Corporate Objectives and Provides Pipeline Update
12:30pm, Thursday, 05'th Mar 2020
Conference Call and Webcast Scheduled Today at 8:45 AM ET WARMINSTER, Pa., March 05, 2020 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV).
The Week Ahead In Biotech: COVID-19 Stocks In The Spotlight, Earnings Taper Off
07:52pm, Saturday, 29'th Feb 2020
Biotech stocks came under significant weakness along with the broader market in the week ended Feb. 28. Despite fears the COVID-19 epidemic will likely drag global growth, the viral outbreak proved ad
Arbutus to Report Fourth Quarter and Year-End 2019 Financial Results
01:00pm, Thursday, 27'th Feb 2020
WARMINSTER, Pa., Feb. 27, 2020 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled.
Global Gene Therapy Market Projected to Grow with a CAGR of 34.8% During the Forecast Period, 2019-2026 - ResearchAndMarkets.com
03:48pm, Tuesday, 25'th Feb 2020
The "Gene Therapy Market by Vector Type, Gene Type and Application: Global Opportunity Analysis and Industry Forecast, 2019-2026" report has been added to ResearchAndMarkets.com's offering.
PLUG, Z among premarket gainers
02:17pm, Thursday, 20'th Feb 2020
Brickell Biotech (NASDAQ:BBI) +64% on positive sofpironium bromide data.Adesto Technologies (NASDAQ:IOTS) +55% on being acquired by Dialog Semiconductor.Stamps.com (NASDAQ:STMP) +39% on Q4 results.
Investment Analysts' New Coverage for February, 19th (ABUS, AEE, AEP, CNP, D, ES, ETR, EXC, ITCI, NEE)
11:28pm, Wednesday, 19'th Feb 2020
Investment Analysts’ new coverage for Wednesday, February 19th: Robert W. Baird initiated coverage on shares of Arbutus Biopharma (NASDAQ:ABUS). The firm issued an outperform rating on the stock. BM
Stock Charts To Watch - Wednesday, February 5
02:00am, Thursday, 06'th Feb 2020
Puma Biotechnology, Inc. exploded Wednesday, jumping 3.98 or 38%, to 14.56, after reaching a high of 15.00, on a whopping 23 million shares traded.
6 Biotechnology Stocks Moving In Wednesday's Pre-Market Session
12:42pm, Wednesday, 05'th Feb 2020
Gainers
• Moleculin Biotech, Inc. (NASDAQ:MBRX) stock rose 35.2% to $1.19 during Wednesday's pre-market session.
• Arbutus Biopharma, Inc. (NASDAQ:ABUS) shares rose...
Arbutus Biopharma (NASDAQ:ABUS) and GlycoMimetics (NASDAQ:GLYC) Head-To-Head Contrast
06:46am, Friday, 17'th Jan 2020
Arbutus Biopharma (NASDAQ:ABUS) and GlycoMimetics (NASDAQ:GLYC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of th
